More on FATE
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $2.52 |
|
|||
| Open | $2.58 | ||||
| 52 Wk High | $4.76 | ||||
| 52 Wk Low | $1.46 | ||||
| Day High | $2.60 | ||||
| Day Low | $2.48 | ||||
| P/E | N/A | ||||
| EPS | $-1.91 | ||||
| Volume | 1,995,031 | ||||
- Fate Therapeutics (FATE) PT Raised to $3.50 at Wells Fargo
- Fate Therapeutics (FATE) PT Raised to $8 at Piper Sandler
- Fate Therapeutics starts Phase 2 lupus nephritis trial of FT819
- Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis
- Form S-8 FATE THERAPEUTICS INC
- Form 10-Q FATE THERAPEUTICS INC For: Jun 30
- Form 8-K FATE THERAPEUTICS INC For: Aug 13
- Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
- Form 4 FATE THERAPEUTICS INC For: Aug 04 Filed by: TAHL CINDY
- Form 4 FATE THERAPEUTICS INC For: Aug 04 Filed by: Valamehr Bahram
Entities mentioned with FATE
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Jefferies & Co | View Related Stories »
- S3 | View Related Stories »
- 13G | View Related Stories »
- ARK | View Related Stories »
- Definitive Agreement | View Related Stories »
- Maynard Um | View Related Stories »
- Show More...
